Novartis Fights MSN’s Push to Delist Revived Entresto Patent

Novartis AG is fighting MSN Laboratories Pvt. Ltd.'s efforts to pull a revived patent from Entresto’s entry in the FDA’s Orange Book, urging a Delaware federal judge to toss the generic-drug maker’s “improper” counterclaim.

MSN’s attempt to delist US Patent No. 8,101,659 from the US Food and Drug Administration’s registry of approved drugs is legally flawed because the underlying lawsuit concerns standard patent-infringement claims rather than Hatch-Waxman allegations, the Swiss drugmaker said Wednesday in a brief supporting its motion to dismiss in the US District Court for the District of Delaware. Novartis also separately asked the court to reject MSN’s ...